Recombinant DNA Advisory Committee. U.S. Department of Health and Human Services, Public Health Service, National Institute of Health.
D026683:Advisory Committees / Q000458:organization & administration; D000818:Animals; D002986:Clinical Trials as Topic / Q000009:adverse effects / Q000331:legislation & jurisprudence / Q000379:methods / Q000592:standards; D004274:DNA, Recombinant; D016208:Databases, Factual; D003929:Diabetic Neuropathies / Q000235:genetics / Q000628:therapy; D005818:Genetic Engineering / Q000009:adverse effects / Q000331:legislation & jurisprudence* / Q000379:methods / Q000592:standards*; D015316:Genetic Therapy / Q000009:adverse effects / Q000331:legislation & jurisprudence* / Q000379:methods / Q000592:standards*; D017408:Guidelines as Topic / Q000592:standards; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000556:secondary / Q000628:therapy; D051379:Mice; D009316:National Institutes of Health (U.S.); D009362:Neoplasm Metastasis / Q000235:genetics / Q000628:therapy; D012516:Osteosarcoma / Q000235:genetics / Q000556:secondary / Q000628:therapy; D010300:Parkinson Disease / Q000235:genetics / Q000628:therapy; D012107:Research Design / Q000331:legislation & jurisprudence / Q000592:standards; D014481:United States
D004274:DNA, Recombinant